1

45

05

4

Jilin Qijian Bio-pharmaceutical Co., Ltd.

imgboxbg

Product center

Product center

Human growth hormone (HGH)
Butylphthalein (NBP)
Monosialotetrahexosylganglioside sodium (GM1)
Adenosine methionine succinate (SAM)
Qiqingli Peptide

imgboxbg

R & D

R & D

Technology Platform
Technology Team
Scientific Research Results

imgboxbg

Recruiting Talents

Recruiting Talents

News Center

News and information

06 2024-12

THE 3RD WORLD CONFERENCE ON SCIENCE AND TECHNOLOGY OF TCM AND THE 2024 CHANGCHUNINTERNATIONAL MEDICINE& HEALTH INDUSTRY EXPO

THE 3RD WORLD CONFERENCE ON SCIENCE AND TECHNOLOGY OF TCM AND THE 2024 CHANGCHUNINTERNATIONAL MEDICINE& HEALTH INDUSTRY EXPO
27 2024-11

Good news | Jilin Qijian Bio-Pharmaceutical Co., Ltd. passed the pharmaceutical GMP compliance inspection

Our company's butylphthalide API production line has successfully passed the pharmaceutical GMP compliance inspection of the National Medical Products Administration. This successful passing of the GMP compliance inspection is not only a recognition of Qijian's existing production capacity and quality management level, but also opens up a broader space for for the future development of the company.
14 2024-11

Good News! Qijian’s butylphthalide API was granted a registration number

Jilin Qijian’s butylphthalide API was successfully approved for market listing on 12th Nov 2024. this marks a significant progress of our drug research and development. This achievement not only lays a solid foundation for the clinical application of butylphthalide injection, but also opens up a broad prospect for our company in R&D and production in the future. The successful application for the registration number of butylphthalide API is the result of our company's long-term investment and unremitting efforts in the field of drug research and development. On the basis of in-depth research on the pharmacological mechanism of butylphthalide, our R&D team has continuously optimized the production process and quality control standards to ensure the safety and efficacy of the product. At the same time, we also actively communicated and collaborated with China FDA and other relevant departments, declared in strict accordance with the relevant regulations and guidelines, and ultimately obtained this important achievement. In the future, we will continue to increase investment in research and development, deepen cooperation with domestic and foreign research institutions and medical institutions, and promote the research and development and application of innovative medicines, so as to bring benefits to more patients. We will continue to uphold the corporate spirit of ‘Integrity, Innovation and Responsibility’ and commit ourselves to provide patients around the world with safer, more effective and more convenient medicines and services. At the same time, we will also actively fulfil our social responsibility and promote the healthy and sustainable development of the pharmaceutical industry.

About Us

About us

imgboxbg

Culture

Culture

imgboxbg

Honor

Honor

imgboxbg

Development

Development

imgboxbg

Enterprise Style

Enterprise Style

Contact Us

Contact us

Username used for comment:
客户留言
Description:
WeChat

WeChat

Contact Us

Contact Us

ADD: No.707 Chaofan street, High-Tech Industrial Development Zone, Changchun City, Jilin province, China
Service Hotline
0086-431-81285900
Fax:0086-431-88794098
Email:
export@qijianbio.com

Copyright:Jilin Qijian Bio-pharmaceutical Co., Ltd.  by:300.cn  吉ICP备20003293号  SEO

搜索
Search